Consultation on Multi-Stakeholder Platform for improving EU Clinical Trials
Recommendation
5-7 November 2024
Hamburg, Germany
GMP and FDA Compliance in Pharmaceutical Development and IMP Manufacturing
Register now for ECA's GMP Newsletter
The EMA, together with the HMAs and the European Commission, is gradually implementing the priorities of its joint Accelerating Clinical Trials (ACT) initiative. Most recently, the European Commission published supplementary recommendations on "Decentralized Clinical Trials".
Concept Paper and Press Release
One of the ACT initiative's high-priority projects is a multi-stakeholder platform to support discussions in the clinical research landscape, facilitate the advancement of clinical trial methods and approaches, and help identify areas for progress and practical solutions to enable and drive change. A concept paper outlining the proposal for the creation of the platform has been published together with a press release inviting all stakeholders and the public to comment by 3 March 2023. Comments can be submitted directly online via a web form. The form also asks whether the respective stakeholder organisation is interested in participating in this platform.
Related GMP News
05.09.2024Clinical Trials Regulation - Version 6.9 of the Q&As
23.07.2024Pilot Results on Regulatory-Led RWE Generation
23.07.2024ICH M12 Guideline on Drug Interaction Studies
20.06.2024Draft ICH M14 Guideline on Real-World Data for Safety Assessment
20.06.2024Glossary of Terms and Definitions for Innovative Clinical Trials
21.05.2024Real-World Evidence: FDA´s Considerations for Non-Interventional Studies